ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 922,73
0,10%
Dow Jones
38 225,66
0,85%
DAX
17 956,09
0,28%
Brent Oil
84,00
0,44%
Bitcoin
59 392,10
0,46%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Novartis AG (NVS)

  7. Novartis AG (NVS) Actualités

NVS

Novartis (NVS)

Novartis AG
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:NVS
DateHeureSourceTitreSymboleSociété
23/04/202413h25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:NVSNovartis AG
15/04/202420h00PR Newswire (US)New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)NYSE:NVSNovartis AG
11/04/202413h00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNYSE:NVSNovartis AG
10/04/202413h13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:NVSNovartis AG
06/04/202422h16PR Newswire (US)New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNYSE:NVSNovartis AG
15/02/202422h15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:NVSNovartis AG
06/02/202422h52Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNYSE:NVSNovartis AG
06/02/202412h14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNYSE:NVSNovartis AG
02/02/202420h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:NVSNovartis AG
31/01/202413h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
31/01/202413h42Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NYSE:NVSNovartis AG
31/01/202413h38Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:NVSNovartis AG
31/01/202412h28IH Market NewsWalmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and MoreNYSE:NVSNovartis AG
22/01/202407h59Dow Jones NewsSandoz to Acquire Cimerli Business from Coherus for $170 MillionNYSE:NVSNovartis AG
12/01/202412h10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNYSE:NVSNovartis AG
11/01/202419h02Dow Jones NewsCytokinetics Shares Slide as Novartis Reportedly Shies Away From DealNYSE:NVSNovartis AG
08/01/202419h43Dow Jones NewsCytokinetics Shares Jump 16% After WSJ Report of Novartis DealNYSE:NVSNovartis AG
08/01/202416h41Dow Jones NewsNovartis on Track for Record High Close -- Data TalkNYSE:NVSNovartis AG
08/01/202408h01Dow Jones NewsNovartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia TrialNYSE:NVSNovartis AG
05/01/202416h15Dow Jones NewsNovartis to Make Pluvicto Radioligand Therapy at Indianapolis PlantNYSE:NVSNovartis AG
02/01/202413h46Dow Jones NewsVoyager Therapeutics Shares Leap Premarket on Novartis CollaborationNYSE:NVSNovartis AG
11/12/202308h02Dow Jones NewsNovartis Drug Meets Primary Goal in Late-Stage Study for Kidney DiseaseNYSE:NVSNovartis AG
11/12/202301h39PR Newswire (US)Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NYSE:NVSNovartis AG
06/12/202311h14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNYSE:NVSNovartis AG
06/12/202306h18PR Newswire (US)Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNYSE:NVSNovartis AG
05/12/202312h25IH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNYSE:NVSNovartis AG
29/11/202312h18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNYSE:NVSNovartis AG
28/11/202321h08Dow Jones NewsFDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood CellsNYSE:NVSNovartis AG
28/11/202308h12Dow Jones NewsNovartis Raises Mid-Term Sales Growth TargetsNYSE:NVSNovartis AG
13/11/202315h16Dow Jones NewsLegend Biotech Subsidiary in License Agreement With NovartisNYSE:NVSNovartis AG
 Showing the most relevant articles for your search:NYSE:NVS

Dernières Valeurs Consultées

EU
LR
Legrand
EU
DG
Vinci
NYSE
DIS
Walt Disney
EU
BN
Danone
NYSE
MRK
Merck
EU
VK
Vallourec
EU
HO
Thales
EU
AF
Air FranceKLM
EU
VIV
Vivendi
NYSE
NKE
Nike
EU
RNO
Renault
EU
RI
Pernod Ricard
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés